Valeant helped found Philidor in 2013, and most of the drugs it dispensed were from Valeant. Prosecutors alleged Tanner passed inside information to Davenport to bolster Philidor's business.

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned ...

Shares of Bausch + Lomb (NYSE: BLCO) rallied 15.7% as of 3:07 p.m. ET today. The stock is surging today on news the company ...

本次传出出售博士伦的消息，或许与博士康的当下困境密不可分。据报道，博士康现有债务为210亿美元，其中100亿美元将在2027年底前到期。然而由于博士伦是重要的创收子公司，母公司必须通过偿付能力测试，然后才能批准出售。

Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don’t think like your typical corporate board, ...

Andrew Left is fighting a range of criminal and civil charges related to his trading practices, and other investors who make ...

Shares of Valeant Pharmaceuticals surged 15% to $11.21 after the company raised 2017 earnings guidance. The embattled drugmaker raised its full-year adjusted EBITDA forecast to $3.6 billion to $3. ...

While we all hope that businesses large and small are out in the world doing the best job possible to be scandal-free, it’s ...

Eye-care company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial ...

Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with significant debt, as ...

Financial writers report on private equity interest in a potential takeover of Bausch & Lomb, with firms like Blackstone and ...